Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SOPHiA GENETICS SA (Nasdaq: SOPH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. SOPHiA GENETICS files reports such as Form 20-F and Form 6-K with the U.S. Securities and Exchange Commission, offering detailed information on its financial condition, operations, and material announcements related to its AI-powered healthcare technology business.
Recent Form 6-K filings have included unaudited interim condensed consolidated financial statements, management’s discussion and analysis of financial condition and results of operations, and press releases covering quarterly results and business updates. These documents give investors insight into revenue trends, non-IFRS measures such as adjusted gross profit and adjusted EBITDA, geographic revenue breakdowns, and segment information that includes the SOPHiA DDM™ Platform and workflow equipment and services.
Through this page, users can review how SOPHiA GENETICS reports on topics such as platform usage, analysis volumes, regional performance, and capital structure. Filings may also reference warrant liabilities, credit agreements, and other financial instruments, along with discussions of constant currency revenue and other metrics used by management to evaluate performance.
Stock Titan enhances these filings with AI-powered summaries that explain key points in accessible language, helping readers understand complex sections of financial statements and management commentary. Users can quickly identify important themes in SOPHiA GENETICS’ 20-F annual reports, 6-K current reports, and other submissions, and then drill into the original documents for more detail.
In addition, this page offers convenient access to information relevant to governance and capital markets activity, such as exhibits attached to 6-Ks and references to registration statements. While SOPHiA GENETICS is not a U.S. domestic issuer and does not file Forms 10-K or 10-Q, its 20-F and 6-K filings serve a similar role for investors analyzing SOPH stock and the company’s AI-driven precision medicine platform.
An insider associated with SOPH has filed a notice of proposed sales under Rule 144 for up to 57,001 shares of common stock, with an indicated aggregate market value of 308,945.42. These shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ, with an approximate sale date of 01/22/2026, and the issuer has 67,847,058 shares outstanding.
The filing shows that 37,001 shares were acquired on 01/22/2026 through an exercise of stock options for cash, and 20,000 founder shares were acquired on 03/18/2021. It also lists a series of prior sales over the past three months under a Rule 10b5-1 trading plan, including individual transactions such as 95,488 shares sold on 01/09/2026 for 491,626.46.
An insider of the issuer of SOPH common stock has filed a Rule 144 notice to sell 7,485 shares of common stock through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $40,793.25. The filing states that 67,847,058 shares of common stock were outstanding and lists an approximate sale date of January 20, 2026 on the NASDAQ exchange.
The securities to be sold include 2,999 shares acquired on January 20, 2026 via exercise of stock options for cash, and 4,486 shares acquired on January 18, 2026 as restricted stock units. The notice also details a series of prior Rule 10b5-1 plan sales for Jurgi Camblong over the past three months, with multiple transactions of common stock on various dates from October 2025 through January 2026, each showing the number of shares sold and related gross proceeds.
A shareholder filed a Rule 144 notice to sell 760 shares of common stock with an aggregate market value of $4,142.00 through Morgan Stanley Smith Barney LLC on NASDAQ.
The shares to be sold were acquired as restricted stock units from the issuer on 01/18/2026, with 760 securities recorded as acquired. The filing notes total common shares outstanding of 67,847,058, providing context for the planned sale.
Over the prior three months, 10b5-1 sales for Ross J. Muken included multiple common stock transactions, such as 4,200 shares sold on 01/06/2026 for gross proceeds of $20,013.84, along with several smaller sales in late 2025.
Zhenyu Xu has filed a Form 144 to sell 4,608 shares of SOPH common stock. The planned sale is to be executed through Morgan Stanley Smith Barney LLC on the NASDAQ exchange, with an aggregate market value of $25,113.60 and an approximate sale date of 01/20/2026.
The shares to be sold include stock acquired as restricted stock units on 01/18/2026 (608 shares) and founders shares acquired on 06/20/2012 (4,000 shares. In the past three months, Xu has already completed multiple Rule 10b5-1 sales of SOPH common stock, including 4,000 shares on 01/13/2026 for $20,682.40, along with several smaller transactions.
A holder of common stock has filed a Form 144 indicating an intent to sell 5,608 shares through Morgan Stanley Smith Barney on the NASDAQ, with an approximate sale date of 01/20/2026 and an aggregate market value of $30,563.60. These shares were acquired as restricted stock units from the issuer on 04/18/2024.
The notice also lists recent Rule 10b5-1 sales for Philippe Menu, including 5,000–5,006-share transactions on 01/12/2026 and 01/06/2026 and several smaller sales in late 2025, with disclosed gross proceeds for each trade. The filing notes that total common shares outstanding are 67,847,058 at the time of the planned sale.
SOPHiA GENETICS shareholder Daan Guido Maria Van Well has filed a Form 144 notice for a proposed sale of common stock. The filing covers 684 common shares to be sold through Morgan Stanley Smith Barney LLC on or about 01/20/2026, with an aggregate market value of $3,727.80 based on the price used in the notice, and notes that 67,847,058 common shares were outstanding.
The 684 shares come from restricted stock units acquired from the issuer on 01/18/2026. The filing also lists recent activity under Rule 10b5-1: sales of 2,056 shares for $9,758.39 on 01/06/2026, 2,051 shares for $9,451.21 on 01/05/2026, 684 shares for $3,168.01 on 12/19/2025, and 685 shares for $2,755.14 on 11/19/2025, all in SOPHiA GENETICS common stock.
An affiliate of SOPH has filed a Rule 144 notice to sell 380 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 01/20/2026. The filing lists an aggregate market value of $2,071.00 for this planned sale and shows that the shares were acquired as restricted stock units from the issuer on 01/18/2026.
The notice also details prior sales under a Rule 10b5‑1 trading plan for Manuela Valente over the past three months, including 636 shares sold on 01/06/2026 for $3,015.72, 2,085 shares sold on 01/05/2026 for $9,603.93, 381 shares sold on 12/19/2025 for $1,764.45, and 381 shares sold on 11/19/2025 for $1,530.86.
An insider of SOPH filed a notice under Rule 144 to sell 30,959 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $159,748.44. These shares relate to the company’s common stock listed on NASDAQ, with 67,847,058 shares outstanding and an approximate sale date of 01/16/2026.
The securities to be sold include 23,597 shares acquired on 01/16/2026 via a cash exercise of stock options and 7,362 founder shares originally acquired on 03/18/2021. The filing also lists multiple prior Rule 10b5-1 sales over the past three months, including, for example, 95,488 shares of common stock sold on 01/09/2026 for gross proceeds of $491,626.46.
SOPHiA GENETICS SA reported a leadership change and strong preliminary 2025 results. The company promoted Ross Muken, currently President and a key executive for five years, to Chief Executive Officer effective July 1, 2026. He is expected to succeed co‑founder Dr. Jurgi Camblong, who will move to Executive Chairman of the Board, subject to election at the Annual General Meeting in June 2026.
For the quarter ended December 31, 2025, the company expects revenue of at least $21 million, about a 20% year‑over‑year increase, and more than 105,000 analyses on SOPHiA DDM, up 16% year‑over‑year. For the full year 2025, it expects revenue of about $77 million, an 18% year‑over‑year increase, and over 391,000 analyses, which it calls a company record. These figures are preliminary, unaudited estimates and may change as year‑end closing and audit work are completed, and the company’s independent auditors have not expressed an opinion on them.
SOPHiA GENETICS reported preliminary unaudited results showing fourth quarter 2025 revenue of at least $21 million, about 20% higher than a year earlier, with more than 105,000 SOPHiA DDM™ analyses, up 16% year-over-year. For full year 2025, revenue is expected to be about $77 million, roughly 18% growth, with over 391,000 analyses, a new company record.
For 2026, the company guides to full year revenue between $92 million and $94 million, implying about 20% to 22% growth, and an adjusted EBITDA loss between $29 million and $32 million. Results are preliminary and subject to completion of year-end closing and audit procedures.
The company also announced a leadership transition plan. Ross Muken, currently President and a long-time senior executive, will become CEO effective July 1, 2026, while co‑founder Jurgi Camblong is expected to move to the role of Executive Chairman, subject to election at the Annual General Meeting in June 2026. In addition, Kevin Puylaert will become Chief Sales Officer in January 2026.